When Rahul Kumar, a daily-wage earner from Patna, got his chest X-ray done after months of coughing, a doctor told him he was suffering from tuberculosis (TB). But when he sought a second opinion, he was told he was fine. "I was asked to get more scans done, but I don't have the money or time to run around for multiple tests," says Kumar, 31. Kumar is one of a large demographic of TB patients in India in whom the disease either goes undetected, or who simply drop off the long and expensive treatment cycle. This, in turn, leads to a greater spread of the disease -- and the possibility of mutated, drug-resistant versions.

Rajarajeshwari Kodhandapani has a dream – to screen one million people for diabetic retinopathy (DR) so they can get timely treatment and not risk going blind. She is one of the four co-founders of Artelus, along with tech veterans Vish Durga, Lalit Pant, and Pradeep Walia, who is also a serial entrepreneur. As a former business analyst, she never thought she would become an entrepreneur (though she did want to become a politician at one time). Now, she is part of Artelus, a company that builds advanced screening tools to allow doctors and hospitals to diagnose a greater number of patients in the same time for a variety of diseases. Today, she wants to reach the people they call the "forgotten billion" – those in rural areas who cannot afford healthcare.

Rajarajeshwari Kodandapani has a dream – to screen one million people for diabetic retinopathy (DR) so they can get timely treatment and not risk going blind. She is one of the four co-founders of Artelus, along with tech veterans Vish Durga, Lalit Pant, and Pradeep Walia, who is also a serial entrepreneur. As a former business analyst, she never thought she would become an entrepreneur (though she did want to become a politician at one time). Now, she is part of Artelus, a company that builds advanced screening tools to allow doctors and hospitals to diagnose a greater number of patients in the same time for a variety of diseases.